Phibro Animal Health (PAHC) Stock Forecast, Price Target & Predictions
PAHC Stock Forecast
Phibro Animal Health stock forecast is as follows: an average price target of $18.67 (represents a -15.10% downside from PAHC’s last price of $21.99) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PAHC Price Target
The average price target for Phibro Animal Health (PAHC) is $18.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $17.00. This represents a potential -15.10% downside from PAHC's last price of $21.99.
PAHC Analyst Ratings
According to 3 Wall Street analysts, Phibro Animal Health's rating consensus is 'Buy'. The analyst rating breakdown for PAHC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 1 'Hold' (33.33%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Phibro Animal Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | - | Roth Capital | $18.00 | $12.75 | 41.18% | -18.14% |
| Sep 16, 2022 | - | Barclays | $17.00 | $14.29 | 18.96% | -22.69% |
| Aug 26, 2022 | - | Morgan Stanley | $21.00 | $16.06 | 30.76% | -4.50% |
The latest Phibro Animal Health stock forecast, released on Dec 21, 2022 by Roth Capital company, set a price target of $18.00, which represents a 41.18% increase from the stock price at the time of the forecast ($12.75), and a -18.14% decrease from PAHC last price ($21.99).
Phibro Animal Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $21.99 | $21.99 | $21.99 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Phibro Animal Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Phibro Animal Health's last price of $21.99. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 10, 2024 | Barclays | Underweight | Underweight | Hold |
| Dec 21, 2022 | Roth Capital | - | Buy | Initialise |
| Sep 16, 2022 | Barclays | Underweight | Underweight | Hold |
| Aug 26, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Phibro Animal Health's last stock rating was published by Barclays on May 10, 2024. The company gave PAHC a "Underweight" rating, the same as its previous rate.
Phibro Animal Health Financial Forecast
Phibro Animal Health Revenue Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $249.94M | $231.30M | $255.05M | $245.70M | $244.65M | $232.52M | - | $239.62M | $232.71M | $214.66M | $220.28M | $211.73M | $206.15M | $195.19M | $185.88M | $210.74M | $214.01M | $189.72M | $203.88M | $205.74M |
| Avg Forecast | $308.43M | $303.78M | $299.21M | $294.70M | $277.63M | $270.50M | $264.76M | $246.60M | $260.49M | $253.65M | $240.93M | $242.00M | $256.13M | $246.69M | $241.29M | $232.09M | $250.04M | $230.53M | $215.28M | $201.06M | $214.28M | $208.06M | $205.48M | $189.08M | $191.20M | $207.45M | $218.87M | $199.38M | $206.00M | $214.94M |
| High Forecast | $312.93M | $308.22M | $303.57M | $299.00M | $281.69M | $274.45M | $268.63M | $301.18M | $264.29M | $257.35M | $247.14M | $245.53M | $259.87M | $250.29M | $244.81M | $235.48M | $250.04M | $231.92M | $216.58M | $202.27M | $215.57M | $209.32M | $206.72M | $190.21M | $192.35M | $208.70M | $220.19M | $200.58M | $207.24M | $216.24M |
| Low Forecast | $303.93M | $299.35M | $294.84M | $290.40M | $273.58M | $266.55M | $260.90M | $216.13M | $256.68M | $249.94M | $237.18M | $238.47M | $252.39M | $243.09M | $237.76M | $228.71M | $250.04M | $229.14M | $213.99M | $199.85M | $212.99M | $206.81M | $204.25M | $187.94M | $190.05M | $206.21M | $217.56M | $198.18M | $204.76M | $213.65M |
| # Analysts | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.96% | 1.00% | 1.00% | 1.01% | 1.00% | - | 1.04% | 1.08% | 1.07% | 1.03% | 1.02% | 1.00% | 1.03% | 0.97% | 1.02% | 0.98% | 0.95% | 0.99% | 0.96% |
Phibro Animal Health's average Quarter revenue forecast for Mar 24 based on 1 analysts is $253.65M, with a low forecast of $249.94M, and a high forecast of $257.35M. PAHC's average Quarter revenue forecast represents a 1.48% increase compared to the company's last Quarter revenue of $249.94M (Dec 23).
Phibro Animal Health EBITDA Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $15.70M | $-700.00K | $33.08M | $18.60M | $24.91M | $22.61M | - | $27.68M | $34.49M | $20.37M | $27.00M | $28.78M | $27.40M | $27.43M | $26.84M | $30.57M | $28.98M | $15.19M | $19.92M | $29.81M |
| Avg Forecast | $28.87M | $28.43M | $28.01M | $27.58M | $25.99M | $25.32M | $24.78M | $23.08M | $24.38M | $48.92M | $22.55M | $22.65M | $23.97M | $44.47M | $22.58M | $24.80M | $23.60M | $40.43M | $37.21M | $22.55M | $27.00M | $28.78M | $20.29M | $22.66M | $32.95M | $26.98M | $22.77M | $18.35M | $21.58M | $32.58M |
| High Forecast | $29.29M | $28.85M | $28.41M | $27.99M | $26.37M | $25.69M | $25.14M | $28.19M | $24.74M | $58.70M | $23.13M | $22.98M | $24.32M | $53.37M | $22.91M | $29.76M | $23.60M | $48.51M | $44.65M | $27.06M | $32.40M | $34.54M | $24.35M | $27.19M | $39.54M | $32.37M | $27.32M | $22.02M | $25.90M | $39.10M |
| Low Forecast | $28.45M | $28.02M | $27.60M | $27.18M | $25.61M | $24.95M | $24.42M | $20.23M | $24.02M | $39.13M | $22.20M | $22.32M | $23.62M | $35.58M | $22.25M | $19.84M | $23.60M | $32.34M | $29.76M | $18.04M | $21.60M | $23.02M | $16.23M | $18.13M | $26.36M | $21.58M | $18.22M | $14.68M | $17.26M | $26.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.70% | -0.03% | 1.38% | 0.42% | 1.10% | 0.91% | - | 0.68% | 0.93% | 0.90% | 1.00% | 1.00% | 1.35% | 1.21% | 0.81% | 1.13% | 1.27% | 0.83% | 0.92% | 0.91% |
1 analysts predict PAHC's average Quarter EBITDA for Mar 24 to be $48.92M, with a high of $58.70M and a low of $39.13M. This is 211.56% upper than Phibro Animal Health's previous annual EBITDA (Dec 23) of $15.70M.
Phibro Animal Health Net Income Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $1.27M | $-8.00M | $11.50M | $10.00M | $7.21M | $3.86M | - | $17.69M | $17.46M | $6.53M | $17.12M | $12.16M | $12.80M | $12.30M | $5.64M | $13.50M | $11.89M | $2.52M | $8.80M | $14.85M |
| Avg Forecast | $19.49M | $18.86M | $18.23M | $14.05M | $17.43M | $15.43M | $15.41M | $9.42M | $13.53M | $22.63M | $11.37M | $9.34M | $15.12M | $20.57M | $12.28M | $7.96M | $15.26M | $18.70M | $15.35M | $7.23M | $17.12M | $12.16M | $9.48M | $10.16M | $6.92M | $11.91M | $9.35M | $3.04M | $9.54M | $16.23M |
| High Forecast | $19.86M | $19.22M | $18.58M | $14.31M | $17.76M | $15.72M | $15.70M | $13.46M | $13.79M | $27.15M | $13.47M | $11.37M | $15.41M | $24.68M | $12.51M | $9.55M | $15.26M | $22.44M | $18.42M | $8.68M | $20.55M | $14.59M | $11.38M | $12.20M | $8.31M | $14.30M | $11.21M | $3.65M | $11.44M | $19.48M |
| Low Forecast | $19.12M | $18.50M | $17.88M | $13.78M | $17.10M | $15.14M | $15.12M | $6.28M | $13.28M | $18.10M | $10.10M | $8.12M | $14.84M | $16.46M | $12.05M | $6.37M | $15.26M | $14.96M | $12.28M | $5.79M | $13.70M | $9.73M | $7.59M | $8.13M | $5.54M | $9.53M | $7.48M | $2.43M | $7.63M | $12.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.11% | -0.86% | 0.76% | 0.49% | 0.59% | 0.48% | - | 0.95% | 1.14% | 0.90% | 1.00% | 1.00% | 1.35% | 1.21% | 0.81% | 1.13% | 1.27% | 0.83% | 0.92% | 0.91% |
Phibro Animal Health's average Quarter net income forecast for Mar 24 is $22.63M, with a range of $18.10M to $27.15M. PAHC's average Quarter net income forecast represents a 1676.04% increase compared to the company's last Quarter net income of $1.27M (Dec 23).
Phibro Animal Health SG&A Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $62.91M | $68.50M | $52.90M | $57.00M | $61.54M | $54.96M | - | $52.43M | $48.38M | $50.07M | $50.67M | $49.03M | $48.38M | $48.43M | $42.45M | $48.23M | $49.49M | $47.52M | $53.20M | $42.30M |
| Avg Forecast | $70.19M | $69.13M | $68.09M | $67.07M | $63.18M | $61.56M | $60.25M | $56.12M | $59.28M | $67.07M | $54.83M | $55.07M | $58.29M | $60.97M | $54.91M | $60.97M | $57.00M | $55.43M | $42.51M | $55.43M | $50.67M | $49.03M | $35.83M | $40.01M | $52.09M | $42.56M | $38.89M | $57.42M | $57.64M | $46.24M |
| High Forecast | $71.22M | $70.14M | $69.09M | $68.05M | $64.11M | $62.46M | $61.13M | $68.54M | $60.15M | $80.48M | $56.24M | $55.88M | $59.14M | $73.17M | $55.71M | $73.17M | $57.00M | $66.51M | $51.02M | $66.52M | $60.80M | $58.84M | $43.00M | $48.01M | $62.51M | $51.07M | $46.67M | $68.90M | $69.17M | $55.49M |
| Low Forecast | $69.17M | $68.12M | $67.10M | $66.09M | $62.26M | $60.66M | $59.37M | $49.18M | $58.41M | $53.65M | $53.98M | $54.27M | $57.44M | $48.78M | $54.11M | $48.78M | $57.00M | $44.34M | $34.01M | $44.34M | $40.54M | $39.23M | $28.67M | $32.01M | $41.67M | $34.05M | $31.11M | $45.93M | $46.11M | $36.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.24% | 0.91% | 0.93% | 1.12% | 0.90% | - | 0.95% | 1.14% | 0.90% | 1.00% | 1.00% | 1.35% | 1.21% | 0.81% | 1.13% | 1.27% | 0.83% | 0.92% | 0.91% |
Phibro Animal Health's average Quarter SG&A projection for Mar 24 is $67.07M, based on 1 Wall Street analysts, with a range of $53.65M to $80.48M. The forecast indicates a 6.60% rise compared to PAHC last annual SG&A of $62.91M (Dec 23).
Phibro Animal Health EPS Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.03 | $-0.20 | - | $0.25 | $0.18 | $0.10 | - | $0.44 | $0.43 | $0.16 | $0.42 | $0.30 | $0.32 | $0.30 | $0.14 | $0.33 | $0.29 | $0.06 | $0.22 | $0.37 |
| Avg Forecast | $0.48 | $0.46 | $0.45 | $0.35 | $0.43 | $0.38 | $0.38 | $0.23 | $0.33 | $0.29 | $0.28 | $0.23 | $0.37 | $0.34 | $0.30 | $0.26 | $0.38 | $0.35 | $0.33 | $0.29 | $0.31 | $0.35 | $0.28 | $0.20 | $0.23 | $0.34 | $0.29 | $0.24 | $0.36 | $0.43 |
| High Forecast | $0.49 | $0.47 | $0.46 | $0.35 | $0.44 | $0.39 | $0.39 | $0.33 | $0.34 | $0.30 | $0.33 | $0.28 | $0.38 | $0.34 | $0.31 | $0.27 | $0.38 | $0.36 | $0.33 | $0.30 | $0.31 | $0.35 | $0.28 | $0.20 | $0.23 | $0.34 | $0.29 | $0.24 | $0.36 | $0.43 |
| Low Forecast | $0.47 | $0.46 | $0.44 | $0.34 | $0.42 | $0.37 | $0.37 | $0.15 | $0.33 | $0.28 | $0.25 | $0.20 | $0.37 | $0.33 | $0.30 | $0.26 | $0.38 | $0.35 | $0.33 | $0.29 | $0.31 | $0.35 | $0.28 | $0.20 | $0.23 | $0.34 | $0.28 | $0.24 | $0.36 | $0.43 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.11% | -0.87% | - | 0.75% | 0.60% | 0.38% | - | 1.25% | 1.31% | 0.55% | 1.34% | 0.86% | 1.14% | 1.49% | 0.61% | 0.97% | 1.01% | 0.25% | 0.61% | 0.86% |
According to 1 Wall Street analysts, Phibro Animal Health's projected average Quarter EPS for Mar 24 is $0.29, with a low estimate of $0.28 and a high estimate of $0.30. This represents a 820.63% increase compared to PAHC previous annual EPS of $0.03 (Dec 23).
Phibro Animal Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.85 | $10.00 | 440.54% | - |
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
PAHC Forecast FAQ
Is Phibro Animal Health a good buy?
Yes, according to 3 Wall Street analysts, Phibro Animal Health (PAHC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of PAHC's total ratings.
What is PAHC's price target?
Phibro Animal Health (PAHC) average price target is $18.67 with a range of $17 to $21, implying a -15.10% from its last price of $21.99. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Phibro Animal Health stock go up soon?
According to Wall Street analysts' prediction for PAHC stock, the company can go down by -15.10% (from the last price of $21.99 to the average price target of $18.67), down by -4.50% based on the highest stock price target, and down by -22.69% based on the lowest stock price target.
Can Phibro Animal Health stock reach $30?
PAHC's average twelve months analyst stock price target of $18.67 does not support the claim that Phibro Animal Health can reach $30 in the near future.
What are Phibro Animal Health's analysts' financial forecasts?
Phibro Animal Health's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $1.06B (high $1.13B, low $1.02B), average EBITDA is $99.17M (high $105.39M, low $95.2M), average net income is $57.68M (high $62.64M, low $53.63M), average SG&A $241.12M (high $256.24M, low $231.48M), and average EPS is $1.42 (high $1.54, low $1.32). PAHC's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $1.21B (high $1.22B, low $1.19B), average EBITDA is $112.89M (high $114.54M, low $111.24M), average net income is $70.62M (high $71.96M, low $69.28M), average SG&A $274.48M (high $278.49M, low $270.48M), and average EPS is $1.74 (high $1.77, low $1.71).
Did the PAHC's actual financial results beat the analysts' financial forecasts?
Based on Phibro Animal Health's last annual report (Jun 2023), the company's revenue was $977.89M, which missed the average analysts forecast of $1.23B by -20.25%. Apple's EBITDA was $108.49M, missing the average prediction of $139.43M by -22.19%. The company's net income was $32.61M, missing the average estimation of $71.19M by -54.20%. Apple's SG&A was $226.39M, missing the average forecast of $292.15M by -22.51%. Lastly, the company's EPS was $0.81, missing the average prediction of $1.65 by -50.91%. In terms of the last quarterly report (Dec 2023), Phibro Animal Health's revenue was $249.94M, beating the average analysts' forecast of $240.93M by 3.74%. The company's EBITDA was $15.7M, missing the average prediction of $22.55M by -30.37%. Phibro Animal Health's net income was $1.27M, missing the average estimation of $11.37M by -88.79%. The company's SG&A was $62.92M, beating the average forecast of $54.83M by 14.75%. Lastly, the company's EPS was $0.0315, missing the average prediction of $0.28 by -88.75%